Skip to main content
Clinical Trials/NCT03254147
NCT03254147
Completed
Not Applicable

Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)

Boehringer Ingelheim1 site in 1 country53,969 target enrollmentOctober 15, 2017

Overview

Phase
Not Applicable
Intervention
warfarin
Conditions
Atrial Fibrillation
Sponsor
Boehringer Ingelheim
Enrollment
53969
Locations
1
Primary Endpoint
The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF

Detailed Description

This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF, the incidence rates of emergency surgery, major bleeding due to trauma, and major bleeding due to fracture, overall and stratified by age (\<64, 65-74, \>75). The secondary objective is to estimate the overall and age stratified incidence of cardiac tamponade and peri-cardiocentesis.

Registry
clinicaltrials.gov
Start Date
October 15, 2017
End Date
November 10, 2017
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • \>18 year old non-valvular atrial fibrillation (NVAF) patients
  • Prescribed dabigatran, rivaroxaban, apixaban, edoxaban or warfarin
  • Patients with confirmed date of initiation of OACs
  • Patients with a minimum of 6 months of enrolment data prior to index date
  • Has an index date between 14th of March 2011 to 30 June, 2016

Exclusion Criteria

  • Patients receiving two or more oral anti-coagulants at the same time at index date
  • Patients with prescriptions of index treatment in the 6 months prior to index date
  • Patients without enrolment period of at least six month in the database

Arms & Interventions

patients prescribed with Oral Anti-coagulants

warfarin and non-vitamin K dependent oral anti-coagulants

Intervention: warfarin

patients prescribed with Oral Anti-coagulants

warfarin and non-vitamin K dependent oral anti-coagulants

Intervention: dabigatran

patients prescribed with Oral Anti-coagulants

warfarin and non-vitamin K dependent oral anti-coagulants

Intervention: Apixaban

patients prescribed with Oral Anti-coagulants

warfarin and non-vitamin K dependent oral anti-coagulants

Intervention: Edoxaban

patients prescribed with Oral Anti-coagulants

warfarin and non-vitamin K dependent oral anti-coagulants

Intervention: Rivaroxaban

Outcomes

Primary Outcomes

The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.

Time Frame: One year

The number of patients with emergency surgery and major bleeding due to fracture or trauma. Where emergency surgery defined as any surgical procedure (International Classification of Diseases (ICD) 10 code K000-879) performed on the same day as hospital admission with additional claims, major bleeding due to fracture is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any fracture, and major bleeding due to trauma is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any trauma.

Secondary Outcomes

  • The Number of Patients With Cardiac Tamponade and Pericardiocentesis.(One year)

Study Sites (1)

Loading locations...

Similar Trials